180 related articles for article (PubMed ID: 38534371)
21. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
Jaiswal A; Jaiswal A; Williamson EA; Gelfond J; Zheng G; Zhou D; Hromas R
Cancer Chemother Pharmacol; 2023 Jan; 91(1):89-95. PubMed ID: 36346454
[TBL] [Abstract][Full Text] [Related]
22. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
25. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
26. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract][Full Text] [Related]
27. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
28. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
[TBL] [Abstract][Full Text] [Related]
29. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
Lakhani NJ; Rasco D; Wang H; Men L; Liang E; Fu T; Collins MC; Min P; Yin Y; Davids MS; Yang D; Zhai Y
Clin Cancer Res; 2024 Feb; 30(3):506-521. PubMed ID: 37971712
[TBL] [Abstract][Full Text] [Related]
30. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
32. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
33. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
[TBL] [Abstract][Full Text] [Related]
34. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
Gress V; Roussy M; Boulianne L; Bilodeau M; Cardin S; El-Hachem N; Lisi V; Khakipoor B; Rouette A; Farah A; Théret L; Aubert L; Fatima F; Audemard É; Thibault P; Bonneil É; Chagraoui J; Laramée L; Gendron P; Jouan L; Jammali S; Paré B; Simpson SM; Tran TH; Duval M; Teira P; Bittencourt H; Santiago R; Barabé F; Sauvageau G; Smith MA; Hébert J; Roux PP; Gruber TA; Lavallée VP; Wilhelm BT; Cellot S
Blood Adv; 2024 Jan; 8(1):112-129. PubMed ID: 37729615
[TBL] [Abstract][Full Text] [Related]
35. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
[TBL] [Abstract][Full Text] [Related]
37. Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin.
Cao C; Pei Y; Yu H; Qi H
J Chemother; 2024 Apr; 36(2):156-166. PubMed ID: 37309095
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Rudin CM; Hann CL; Garon EB; Ribeiro de Oliveira M; Bonomi PD; Camidge DR; Chu Q; Giaccone G; Khaira D; Ramalingam SS; Ranson MR; Dive C; McKeegan EM; Chyla BJ; Dowell BL; Chakravartty A; Nolan CE; Rudersdorf N; Busman TA; Mabry MH; Krivoshik AP; Humerickhouse RA; Shapiro GI; Gandhi L
Clin Cancer Res; 2012 Jun; 18(11):3163-9. PubMed ID: 22496272
[TBL] [Abstract][Full Text] [Related]
39. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
40. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
